Deadline to submit a Late-Breaking Clinical Science Abstract: Tuesday, 19 October, 2021 at 11:59 p.m. EDT
Submitted abstracts can be edited until the deadline.
The late-breaking clinical science
category is intended to facilitate the presentation of high-impact multi-center studies or particularly provocative single-center investigations. In general, such studies would include prospective, randomized trials that seek to investigate new approaches to the diagnosis and/or treatment of cardiothoracic diseases relevant to the field and that have the potential to alter our contemporary treatment paradigm.
To assure that truly "late-breaking" information is included in the meeting, authors may submit abstracts describing trials and studies that are not yet completed as of 19 October, 2021
have results and conclusions available by 11 April, 2022
All late-breaking abstracts must be submitted by the 19 October deadline and will serve as a placeholder for the final abstract.
- A study which has results and conclusions by 19 October, 2021 is not considered late-breaking and should be submitted as a research abstract.
- Abstracts presenting an interim analysis of clinical trial data will not be accepted unless the intention to conduct an interim analysis was predetermined in the trial protocol before the study commenced.
- All late-breaking clinical science abstracts accepted for presentation must undergo a final review of the study results and conclusions by the Executive Program Committee the week of 11 April, 2022. ISHLT reserves the final decision regarding scheduling of Late-Breaking Clinical Science presentations.
A late-breaking clinical science abstract submission must include the following information (limited to 2,140 characters, not including spaces):
- Statement of Purpose of the study (goal or hypothesis being tested)
- Methods and Procedures used
Note: abstracts undergo a blind review process; therefore, abstain from using institution names within the abstract. If accepted, you may update your presentation accordingly.
The Full Name, Affiliation, Email Address, and Disclosure Statement for the Presenting Author and each co-author must be included. There is no limit to the number of authors, and author information is not counted towards the character limit.
The Submitting Author
is responsible for notifying all named co-authors that they will be listed as a co-author on a submitted abstract.
The Presenting Author
will be the only author to receive notification of acceptance/rejection of a submitted abstract; therefore, it is the Presenting Author's responsibility to notify all co-authors regarding the outcome of an abstract submission.
A late-breaking clinical science abstract may be submitted into one of four Core Therapies
- Advanced Heart Failure and Transplantation (HEART)
- Advanced Lung Failure and Transplantation (LUNG)
- Mechanical Circulatory Support (MCS)
- Pulmonary Vascular Disease (PVD)
Accepted Late-Breaking Clinical Science abstracts will be published exactly as submitted
(i.e. results or conclusions will not be included) in the April 2022 Supplement of the Journal of Heart and Lung Transplantation
. If you would like an updated version of your abstract with interim results
published, you must submit these results to email@example.com
no later than 4 February, 2022
Visit our FAQ Page
for answers to common submission questions.